In this issue:
Tofacitinib for refractory dermatomyositis
Vitamin K antagonists increase OA incidence/progression
Warfarin and risk of knee and hip replacement for OA
Intensive vs. standard BP control: final analysis
Antibiotics for 6 or 12 weeks for prosthetic joint infection
Upadacitinib for moderate-to-severe atopic dermatitis
Etanercept or methotrexate withdrawal in RA patients in sustained remission
Nonsurgical vs. surgical treatment for rotator cuff disease
VTE risk with JAK inhibitors
CV safety of febuxostat
Please login below to download this issue (PDF)